Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats: Possible role of P-gp and CYP3A4 inhibition by HMG-CoA reductase inhibitors.
CONCLUSION: The increased bioavailability of nifedipine may be mainly due to inhibition of both P-gp in the small intestine and CYP3A subfamily-mediated metabolism of nifedipine in the small intestine and/or in the liver and to the reduction of the CL/F of nifedipine by fluvastatin and simvastatin.
PMID: 25560574 [PubMed - in process]
Source: Pharmacological Reports - Category: Drugs & Pharmacology Authors: Lee CK, Choi JS, Choi DH Tags: Pharmacol Rep Source Type: research
More News: Atorvastatin Calcium | Drugs & Pharmacology | Fluvastatin | Lipitor | Liver | Nifedipine | Pravastatin | Simvastatin | Statin Therapy | Study | Urology & Nephrology | Zivast | Zocor